Amendments to the Claims

Please add new claims 15-40 as presented below in the listing of claims. Please cancel claims 1-14 without prejudice. This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of claims:

1-14. (canceled)

15. (new) A composition comprising at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

16. (new) A composition according to claim 15, further comprising a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and

comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

17. (new) A composition according to claim 16, further comprising a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

18. (new) A composition according to claim 17, further comprising a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

19. (new) A composition according to claim 18, further comprising a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

20. (new) A composition according to claim 19, further comprising a eighth peptide, wherein said eighth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

21. (new) A composition according to claim 20, further comprising a ninth peptide, wherein said ninth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2)
YLQLVFGIEV (SEQ ID NO:3)
LLTFWNPPV (SEQ ID NO:4)
SMPPPGTRV (SEQ ID NO:5)
KLBPVQLWV (SEQ ID NO:6)
KVFGSLAFV (SEQ ID NO:7)
YLSGADLNL (SEQ ID NO:8)

IMIGHLVGV (SEQ ID NO:9)
KVAEIVHFL (SEQ ID NO:10).

22. (new) A composition according to claim 15, further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises an helper T lymphocyte (HTL) epitope.

23. (new) A composition according to claim 22, wherein said additional peptide is a PanDR binding peptide.

24. (new) A composition according to claim 23, wherein said Pan DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).

25. (new) A composition according to claim 15, further comprising a liposome.

26. (new) A composition according to claim 15, further comprising a lipid.

27. (new) A composition according to claim 15, further comprising an antigen presenting cell.

28. (new) A composition according to claim 27, wherein said antigen presenting cell is a dendritic cell.

29. (new) A composition according to claim 15, further comprising a pharmaceutical excipient.

30. (new) A composition according to claim 29, wherein said pharmaceutical excipient is an adjuvant.

31. (new) A composition according to claim 30, wherein said adjuvant is a mineral oil adjuvant.

32. (new) An isolated nucleic acid encoding at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV (SEQ ID NO:2),
YLQLVFGIEV (SEQ ID NO:3),
LLTFWNPPV (SEQ ID NO:4),
SMPPPGTRV (SEQ ID NO:5),
KLBPVQLWV (SEQ ID NO:6),
KVFGSLAFV (SEQ ID NO:7),
YLSGADLNL (SEQ ID NO:8),
IMIGHLVGV (SEQ ID NO:9), and
KVAEIVHFL (SEQ ID NO:10).

33. (new) A method for the treatment or prevention of cancer, said method comprising administering the composition of claim 15 to a patient in need thereof.

34. (new) A method according to claim 33, wherein said treatment delays the recurrence of cancer following surgery, radiation therapy or chemotherapy.

35. (new) A method according to claim 33, wherein said treatment prevents the metastasis of a primary tumor.

36. (new) A method according to claim 33, wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.

37. (new) A method for the treatment or prevention of cancer, said method comprising administering the nucleic acid of claim 32 to a patient in need thereof.

38. (new) A method according to claim 37, wherein said treatment delays the recurrence of cancer following surgery, chemotherapy or radiation.

39. (new) A method according to claim 37, wherein said treatment prevents the metastasis of a primary tumor.

40. (new) A method according to claim 37, wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.